Conjugated hyperbilirubinemia is associated with increased morbidity and mortality after neonatal heart surgery

Cardiol Young. 2024 May;34(5):1083-1090. doi: 10.1017/S1047951123004158. Epub 2023 Dec 18.

Abstract

Background: Cholestasis characterised by conjugated hyperbilirubinemia is a marker of hepatobiliary dysfunction following neonatal cardiac surgery. We aimed to characterise the incidence of conjugated hyperbilirubinemia following neonatal heart surgery and examine the effect of conjugated hyperbilirubinemia on post-operative morbidity and mortality.

Methods: This was a retrospective study of all neonates who underwent surgery for congenital heart disease (CHD) at our institution between 1/1/2010 and 12/31/2020. Patient- and surgery-specific data were abstracted from local registry data and review of the medical record. Conjugated hyperbilirubinemia was defined as perioperative maximum conjugated bilirubin level > 1 mg/dL. The primary outcome was in-hospital mortality. Survival analysis was conducted using the Kaplan-Meier survival function.

Results: Conjugated hyperbilirubinemia occurred in 8.5% of patients during the study period. Neonates with conjugated hyperbilirubinemia were more likely to be of younger gestational age, lower birth weight, and non-Caucasian race (all p < 0.001). Patients with conjugated hyperbilirubinemia were more likely to have chromosomal and non-cardiac anomalies and require ECMO pre-operatively. In-hospital mortality among patients with conjugated hyperbilirubinemia was increased compared to those without (odds ratio 5.4). Post-operative complications including mechanical circulatory support, reoperation, prolonged ventilator dependence, and multi-system organ failure were more common with conjugated hyperbilirubinemia (all p < 0.04). Patients with higher levels of conjugated bilirubin had worst intermediate-term survival, with patients in the highest conjugated bilirubin group (>10 mg/dL) having a 1-year survival of only 6%.

Conclusions: Conjugated hyperbilirubinemia is associated with post-operative complications and worse survival following neonatal heart surgery. Cholestasis is more common in patients with chromosomal abnormalities and non-cardiac anomalies, but the underlying mechanisms have not been delineated.

Keywords: CHD; cardiac surgery; conjugated hyperbilirubinemia; operative mortality.

MeSH terms

  • Bilirubin / blood
  • Cardiac Surgical Procedures* / adverse effects
  • Female
  • Gestational Age
  • Heart Defects, Congenital* / mortality
  • Heart Defects, Congenital* / surgery
  • Hospital Mortality*
  • Humans
  • Hyperbilirubinemia / epidemiology
  • Incidence
  • Infant, Newborn
  • Male
  • Morbidity / trends
  • Postoperative Complications* / epidemiology
  • Retrospective Studies
  • Risk Factors

Substances

  • Bilirubin